Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 in Unresectable Stage 3 or Stage 4 Malignant Melanoma
NCT00429312Phase 2Completed
- Sponsor
- Jennerex Therapeutics
- Start
- Feb 2007
- Primary completion
- Feb 2008
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in melanoma, sponsored by Jennerex Therapeutics. Started Feb 2007; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00429312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429312.